Gilead invests $5 billion to deepen ties with biotech Galapagos

Go back to Gilead invests $5 billion to deepen ties with biotech Galapagos

Galapagos NV (GLPG) PT Raised to $205 at H.C. Wainwright

July 15, 2019 7:30 AM EDT

H.C. Wainwright analyst Debjit Chattopadhyay raised the price target on Galapagos NV (NASDAQ: GLPG) to $205.00 (from $105.00) while maintaining a Buy rating.

The analyst commented, "Having missed the acquisition boat, Gilead (GILD; not rated) forks up billions to shore up and diversify its pipeline. Given GIlead's internal issues, management overhaul, the unknowns heading into the FINCH Phase 3 readouts, and the questionable valuation for its last M&A foray, it is no surprise the team was gun shy from an M&A perspective. With the $5.1B R&D collaboration announced on July 14,... More

Galapagos NV (GLPG) PT Raised to $188 at Cantor Fitzgerald on Gilead Deal

July 15, 2019 6:52 AM EDT

Cantor Fitzgerald analyst Eliana Merle raised the price target on Galapagos NV (NASDAQ: GLPG) to $188.00 (from $130.00) while maintaining an Overweight rating, saying the transformative Gilead deal sets stage for building next pillars of growth.

Merle commented, "We think this historic... More

Citi Reiterates Buy Rating on Galapagos NV (GLPG)

July 15, 2019 3:11 AM EDT

Citi analyst Nick Nieland reiterated a Buy rating and EUR140.00 price target on Galapagos NV (GLPG:NA) (NASDAQ: GLPG).

The analyst comments ..."the investment from Gilead de-risks the Galapagos story and is a significant step towards establishing itself as an independent... More